Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
458-24-2
Molecular formula
C12H16F3N
Molecular weight
231.26 g/mol
Drug class
Serotonergic antiseizure medicineserotonin-releasing agent and 5-HT receptor modulator
Mechanism of action
The precise mechanism by which fenfluramine reduces seizures in Dravet syndrome and Lennox-Gastaut syndrome is not fully established. It enhances serotonergic signalling, including activity at 5-HT receptors, and may also modulate sigma-1 receptor signalling.
Indications / reported uses
Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older
Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older; use requires product-specific cardiac monitoring because of valvular heart disease and pulmonary arterial hypertension risks
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Fenfluramine Environmental Risk Assessment (ERA) (the Fenfluramine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.